文献速递骨软组织肉瘤与黑色素瘤

体内E2F报告系统揭示MEK1/2-CDK4/6靶向治疗的有效方案及mTOR-S6耐药机制

In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms.
PubMed 文献 · Cancer Discov · 2018-03-01

该研究利用体内定量和时间报告系统,在黑色素瘤模型中比较MEK抑制剂联合CDK4/6抑制剂的给药方案,发现持续MEKi联合间歇CDK4/6i获得更完全的肿瘤缓解。部分肿瘤出现耐药,与核糖体S6蛋白磷酸化增强相关,mTORC1/2抑制剂AZD2014可克服耐药。NRAS上调或突变与耐药相关。

要点

  • 持续MEKi联合间歇CDK4/6i较其他方案诱导更完全的肿瘤缓解。
  • 耐药与S6磷酸化增强相关,mTORC1/2抑制剂可提供治疗窗口。
  • NRAS上调或突变与耐药相关,突变NRAS足以增强耐药。

核心结论

  • 持续MEKi联合间歇CDK4/6i方案较其他联合方案获得更完全的肿瘤缓解。
  • 部分肿瘤耐药与核糖体S6蛋白磷酸化增强相关,mTORC1/2抑制剂AZD2014可提供治疗窗口。
  • NRAS上调或突变与耐药相关,突变NRAS足以增强耐药。

研究设计与样本

  • 研究采用定量和时间体内报告系统,在黑色素瘤模型中进行。
  • 研究比较了持续MEKi联合间歇CDK4/6i与其他联合方案。
  • 研究分析了耐药肿瘤的磷酸化S6染色及患者黑色素瘤活检样本。

主要发现

  • 持续MEKi联合间歇CDK4/6i较其他方案获得更完全的肿瘤缓解。
  • 耐药肿瘤中核糖体S6蛋白磷酸化增强。
  • 患者接受CDK4/6i联合靶向抑制剂治疗的黑色素瘤活检磷酸化S6染色支持上述数据。
  • NRAS上调或突变分别与体内模型和患者样本中的耐药相关。
  • 突变NRAS足以增强耐药。

关键数值与推荐

  • 耐药肿瘤中磷酸化S6增强为mTORC1/2抑制剂AZD2014提供治疗窗口。

临床怎么用

  • 支持利用mTORC1/2抑制剂克服MEKi联合CDK4/6i耐药。
  • 为优化MEKi联合CDK4/6i给药方案提供临床前依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Targeting cyclin-dependent kinases 4/6 (CDK4/6) represents a therapeutic option in combination with BRAF inhibitor and/or MEK inhibitor (MEKi) in melanoma; however, continuous dosing elicits toxicities in patients. Using quantitative and temporal in vivo reporting, we show that continuous MEKi with intermittent CDK4/6 inhibitor (CDK4/6i) led to more complete tumor responses versus other combination schedules. Nevertheless, some tumors acquired resistance that was associated with enhanced phosphorylation of ribosomal S6 protein. These data were supported by phospho-S6 staining of melanoma biopsies from patients treated with CDK4/6i plus targeted inhibitors. Enhanced phospho-S6 in resistant tumors provided a therapeutic window for the mTORC1/2 inhibitor AZD2014. Mechanistically, upregulation or mutation of NRAS was associated with resistance in in vivo models and patient samples, respectively, and mutant NRAS was sufficient to enhance resistance. This study utilizes an in vivo reporter model to optimize schedules and supports targeting mTORC1/2 to overcome MEKi plus CDK4/6i resistance.Significance: Mutant BRAF and NRAS melanomas acquire resistance to combined MEK and CDK4/6 inhibition via upregulation of mTOR pathway signaling. This resistance mechanism provides the preclinical basis to utilize mTORC1/2 inhibitors to improve MEKi plus CDK4/6i drug regimens. Cancer Discov; 8(5); 568-81. ©2018 AACR.See related commentary by Sullivan, p. 532See related article by Romano et al., p. 556This article is highlighted in the In This Issue feature, p. 517.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Teh JLF, Cheng PF, Purwin TJ, et al. In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms. Cancer Discov. 2018. PMID: 29496664. doi:10.1158/2159-8290.CD-17-0699

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。